Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diacerein SCHEMBL29944894 | 1.00 | TTR (1.00) | TTRALDH1A1KDM4EHPGDMEN1 | |
| Diacerein SCHEMBL5051685 | 1.00 | TTR (1.00) | TTRALDH1A1KDM4EHPGDMEN1 | |
| Diacerein SCHEMBL25784 | 1.00 | TTR (1.00) | TTRALDH1A1KDM4EHPGDMEN1 | |
| Diacerein SCHEMBL7438555 | 0.99 | TTR (0.97) | TTRALDH1A1KDM4EHPGDMEN1 | |
| Diacerein SCHEMBL5078956 | 0.99 | TTR (0.97) | TTRALDH1A1KDM4EHPGDMEN1 | |
| Diacerein SCHEMBL787907 | 0.99 | TTR (0.97) | TTRALDH1A1KDM4EHPGDMEN1 | |
| Diacerein SCHEMBL2326532 | 0.93 | TTR (0.86) | TTRALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL23655432 | 0.92 | TTR (0.84) | TTRALDH1A1KDM4EHPGDMEN1 | |
| Diacerein SCHEMBL5712120 | 0.92 | MEN1 (0.84) | TTRALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL16549421 | 0.90 | TTR (0.82) | TTRALDH1A1KDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | claimed |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-10-14 | — | — | US | claimed |
| CN-119713758-B | Natural gas liquefaction system and process with cascade refrigeration | 杭州中泰深冷技术股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-4531911-A1 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | claimed |
| CN-119713758-A | Natural gas liquefaction system and process with cascade refrigeration | 杭州中泰深冷技术股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119529387-A | Modified In2O3Is a process for producing the same and a modified In containing the same2O3Thermoplastic resin composite material of (2) | 合肥杰事杰新材料股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119278052-A | Preventing or alleviating adverse reactions associated with T cell cements | 豪夫迈·罗氏有限公司 | 2025-01-07 | — | — | CN | claimed |
| WO-2024263790-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| CN-118703026-A | High-performance low-warpage PET composite material and preparation method thereof | 合肥纳仕捷新能源科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-117362905-A | ABS composite material with antibacterial and antistatic properties and preparation method thereof | 合肥杰事杰新材料股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-20230416412-A1 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | HOFFMANN-LA ROCHE INC. (US) | 2023-12-28 | — | — | US | claimed |
| WO-2023232752-A1 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-07 | — | — | WO | claimed |
| CN-116925461-A | Wear-resistant antistatic glass fiber reinforced polypropylene composite material and preparation method thereof | 合肥杰事杰新材料股份有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-115353685-B | High-performance low-warpage PP (Polypropylene) plate and preparation method thereof | 江西同益高分子材料科技有限公司 | 2023-10-17 | — | — | CN | claimed |
| CN-108334118-B | Ammonia water concentration control system and method at outlet of high-pressure absorption tower in ethanolamine device | 中石化宁波工程有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-03 | — | — | US | claimed |
| CN-115353685-A | High-performance low-warpage PP (polypropylene) plate and preparation method thereof | 江西同益高分子材料科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20220275079-A1 | Clonal Hematopoiesis and Risk of Chronic Liver Disease | THE GENERAL HOSPITAL CORPORATION | 2022-09-01 | — | — | US | claimed |
| EP-3993781-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO TDP-43, ALPHA-SYNUCLEIN, HUNTINGTIN'S PROTEIN AND TAU PROTEIN OLIGOMER FORMATION | Acelot, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416412-A1 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | NLRP3, PYCARD, NLRP1 | TTR 1074/4885ALDH1A1 4461/4885KDM4E 3832/4885 |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | TTR 119/4885ALDH1A1 507/4885KDM4E 1658/4885 |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | RBP4, RBP1, FABP1 | TTR 89/4885ALDH1A1 492/4885KDM4E 1552/4885 |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | TTR 89/4885ALDH1A1 492/4885KDM4E 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.